https://www.selleckchem.com/mTOR.html
nalysis, adjunctive RSDN to PVI appears to be safe, and improvesclinical outcomes in AF patients with a history of hypertension. The pilot HFIB-1 and HFIB-2 studies did not demonstrate a benefit with RSDN as an adjunctive upstream therapy during PVI. However, in the meta-analysis, adjunctive RSDN to PVI appears to be safe, and improves clinical outcomes in AF patients with a history of hypertension. The authors performed a systematic review and meta-analysis to determine the efficacy of renal denervation (RDN) in patients with refractory ventricula
Like
Comment
Share
